Midterm #3 Flashcards
Definition of Bioavailability
- Amount of unchanged drug reaching systemic circulation
- F=bioavailable dose/administered dose
- describes extent to which drug is absorbed
How to Measure Oral Bioavailability
F=(AUCoral/AUCiv)*(Div/Doral)
AUCoral=(F*Doral)/CL
Absolute vs Relative Bioavailability
- Absolute: oral AUC vs. IV AUC
- Relative: two oral formulation AUC
Measuring BA using Urinary Excretion Data
- Ae, iv=feDiv
- Ae,o=feDoF
- F=(Ae,o/Ae, iv)=(Ae,o/fe*D)
- Only applies to drugs with 30% or greater fe
Absorption Extent vs. Absorption Rate
- Extent: how much reaches systemic circulation
- absolute bioavailability (F)
- measured by (AUC/D), Aetotal, Cmax
- Rate: how fast
- ka or t1/2 absorption
- change in these affects Tmax and Cmax, may not affect extent (F, AUC)
Effect of Doubling Dose on Cmax and AUC
Double dose, double AUC and Cmax
Effect of decreasing F on Cmax and AUC
Decrease F, decrease Cmax and AUC proportionally
Effect of decreasing Ka of Tmax and Cmax
increases Tmax and decreases Cmax
Factors Affecting Oral Drug Absorption
- Dissolution
- Membrane Permeability
- First Pass metabolism
- Intestinal efflux and influx transporters
- Drug stability in GI tract
- GI physiology
- Food and other medications
Dissolution Effect on Oral Absorption
- depend on solubility, exciptient, formulation
- affects dissolution
Membrane Permeability Effect of Oral Absorption
- affects intestinal absorption
First Pass Metabolism Effect of Oral Absorption
- Affects intestinal absorption and liver first pass
Follow Pathway of Drug
- green=dissolution
- yellow=membrane permeability
- blue=efflux/influx transporters
- purple=drug stabilty
- pink=GI physiology
- gray=food and other meds

Effect of Formualtion
- Rate Tablet Dissintegration
- Tablet compression, excipients
- Rate of Dissolution
- particle size
- drug solubility
- Modified Release
- reduce frequency of admin
- deliver drug to site of action
Food and Oral Drug Absorption
- Delays gastric emptying
- Gastric secretion
- Bile salt secretion
- Bind Ca2+, reduces absorption
- Can interact with enzymes or transporter
Food and Acid Sensitive Drugs
- decreases Abs
- decreases Cmax
- decreases F
- Take 30-60 min before food
Brand Name Drugs
- A new drug (new chemical entity)
- Approved by FDA under New Drug Applications (NDAs)
- Marketed by the pharmaceutical company under a branded name
- Protected by patents for certain years
- Expensive
Generic Drugs
- Same active drug (chemical entity) as the brand name drug but sold under a different name (often the chemical name of the active drug)
- Approved by FDA under Abbreviated New Drug Applications (ANDAs)
- Cost-saving
1906 Pure Food and Drug Act
established regulation of Food and Drugs.
1938 Federal Food, Drug and Cosmetic (FFD&C) Act
introduced safety standards.
1962 Kefauver-Harris Amendment to the FFD&C Act
tightened safety standards and introduced requirement that drugs must be effective.
1984 Hatch-Waxman Act
- created an abbreviated mechanism (ANDA) for approval of generic versions of brand-name drugs without conducting costly and duplicative pre-clinical and clinical testing.
- increased availability of generics, greatly reduced the cost of prescription drugs
Bioequivalence replaces these 3 things in ANDA
clinical studies, animal studies, bioavailabilty
generic drug definition
- drug product that is comparable to brand/reference listed drug product in:
- dosage form
- strength
- route of administration
- quality and performance characteristics
- intended use
Pharmaceutical Equivalence
- Same active ingredients
- Same route of admin
- Same dosage form
- Same strength
Labeling
Same conditions of use
Therapeutic Equivalence
- Same performance characteristices
- efficacy and saftey
Pharmaceutical Alternative
different salts, esters, dosage form or strength, also ER vs. IR
Therapeutic Interchange
drugs in the same therapeutic class (Atorvastatin vs. Simvistatin)
Does PE=TE
- NO!
- TE=BE+PE
Two products are bioequivalent if
- They are pharmaceutically equivalent
- Systemic absorption (both rate and extent) after administration are not significantly different
BE Testing, Key PK parameters
- Compare Cmax and total exposure
- e.g. drug with very long half-life (e.g. amiodarone)
- e.g. drugs with highly variable PK
- e.g. pt trials and ER/IR
- e.g. topicals, nasal drugs
- Single-dose parallel design
- Single-dose, replicate design
- Multiple-dose, two-way crossover
- Clinical endpoint study
Absorption, Distribution and Elimination barriers
- Absorption:
- Oral: Small intestine mucosal layer
- Topical: Skin: Stratum Corneum
- Intranasal: Nasal Membrane
- Distribution:
- BBB
- placenta
- Elimination:
- Kidney Secretion: proximal tubule epithelium
- Hepatobiliary Secretion: hepatocyte membrane
Paracellular Transport
- indepent of size, charge, lipophilicity
- not for protein bound
- pore transport/filtration
Fick’s First Law of Diffusion
- Jc=P*SA*(Cu1-Cu2)
- Jc=rate of diffusion (mg/min)
- P=permeability (cm/sec)
Permeability Coefficient
- P=(K*D)/delta x
- K=partition coefficient depending on **hydrophobiticity **and charge
- D=diffusion coefficient depending on size and membrane viscosity
- delta x: membrane thickness
too lipophilic and too polar
- too lipophilic:
- insoluable, bind plasma protein
- too polar
- not get though gut wall or BBB
Lipinski Rule of 5
- Poor Abs/Permeability when:
- MW>500
- LogP>5
- 5 H-bond donors
- 10 H-bond acceptors
- Exceptions: substrates relying on drug transporters
Ionization

pH Partition Hypothesis
- only unionized get into equilibrium at membrane
- total concentration on each side depends on ionization degree
- greater iniozation, greater total C
Characteristics of Carrier-Mediated Transport
- specific, inhibitable, saturable
MM equation
- V=(Vmax*S)/(Km+S)
SLC Transporters
- OATPs, OAT, OCT
- Gene: SLC(family #) A (member #)
- Protein: related to function
- Exception: SLCO family (OATP)
ABC Transporters
- P-gp, MDR
- Gene: ABC (family letter)(member #)
- Protein: Reflects function
Importance of Drug Transporters
- determinant of drug disposition and response
- DDI
- Inter-individual intervariability
- Source for non-linear kinetics
P-gp
- efflux transporter
- part of ABC family
- lipophilic, cationic, nuetral, bulky rings
- substrates are ampipathic, MW >400kDa. positive charge at pH 7.4
- inhibited by clarithromycin
- induction of P-gp by rifampin decreases oral absorption
- Pumps drugs back into intestine lumen, decrease oral absorption
- facilitate bilary secretion
- faciitatie renal recretion
- prevent drug into brain
- preven drug into placenta
Drug Elimination in Liver and Drug Transporters

OATPs
- 1b1, 1b3, 2b in liver
- sinusidol side of liver
- drug uptake into liver
- Eliminate statins
- cyclosporin inhibit 1b1
- create 10 fold increase in AUC of statin…myopathies
First Approach to Determining Renal Clearance
- blood and urine collection over several t1/2
- CLr=(Ae/D)*CL=feCL
Second Approach to Determining Renal Clearance
- urine collection over short period and blood collection at midpoint
- CLr=(dA/dt)/Cmid
Renal Clearance from these 3 process
- Glomerular Filtration
- Tubular Secretion
- Tubular Reabsorption
- Rate Exrection=(1-FR)(Rate of Filtration + Rate Secretion)
- FR=fraction reabsorbed from lumen
Glomerular Filtration
- 120 mL/min
- urine flow 1-2 mL/min
- Rate Filtration=GFR*Cu=GFR*fu*C
- Renal Extraction Ratio (E)=CLr/Qr=(120 mL/min)/1200=0.1
- glomerular filtration is a low efficiency process
CLr
- CLr=(fu*GFR)+CLsecretion-CLreabsorption
- CLfiltration=fu*GFR
- if CLr>CLfiltration, net secretion
- if CLr<cl>filtration,net reabsorption</cl>
Organic Kidney Anion Secretion
OAT1/3, MRP, OATP
Organic Kidney Cation Secretin
OCT2 and MATE-1
OCT2, OATP1/3, and P-gp in renal tubular cells
- OCT2 and OATP1/3: from blood to cell
- P-gp: from cell to urine
OAT1/3 inhibitor, interactions
- probenecid
- interacts with beta-lactams, NSAID, diuretics, antiviral, etc.
- transport anionic drugs
OCT2 inhibitor and interactions
- interact wtih cations
- metformin, H2 blockers, endogenous calcium
- inhibited by cimetidine